Research ExplorerPublicationsThe International Multicenter TriValve Registry: Which Patie...

The International Multicenter TriValve Registry: Which Patients Are Undergoing Transcatheter Tricuspid Repair?

Standard

The International Multicenter TriValve Registry: Which Patients Are Undergoing Transcatheter Tricuspid Repair? / Taramasso, Maurizio; Hahn, Rebecca T; Alessandrini, Hannes; Latib, Azeem; Attinger-Toller, Adrian; Braun, Daniel; Brochet, Eric; Connelly, Kim A; Denti, Paolo; Deuschl, Florian; Englmaier, Andrea; Fam, Neil; Frerker, Christian; Hausleiter, Joerg; Juliard, Jean-Michel; Kaple, Ryan; Kreidel, Felix; Kuck, Karl Heinz; Kuwata, Shingo; Ancona, Marco; Malasa, Margarita; Nazif, Tamim; Nickenig, Georg; Nietlispach, Fabian; Pozzoli, Alberto; Schäfer, Ulrich; Schofer, Joachim; Schueler, Robert; Tang, Gilbert; Vahanian, Alec; Webb, John G; Yzeiraj, Ermela; Maisano, Francesco; Leon, Martin B.

In: JACC-CARDIOVASC INTE, Vol. 10, No. 19, 09.10.2017, p. 1982-1990.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Taramasso, M, Hahn, RT, Alessandrini, H, Latib, A, Attinger-Toller, A, Braun, D, Brochet, E, Connelly, KA, Denti, P, Deuschl, F, Englmaier, A, Fam, N, Frerker, C, Hausleiter, J, Juliard, J-M, Kaple, R, Kreidel, F, Kuck, KH, Kuwata, S, Ancona, M, Malasa, M, Nazif, T, Nickenig, G, Nietlispach, F, Pozzoli, A, Schäfer, U, Schofer, J, Schueler, R, Tang, G, Vahanian, A, Webb, JG, Yzeiraj, E, Maisano, F & Leon, MB 2017, 'The International Multicenter TriValve Registry: Which Patients Are Undergoing Transcatheter Tricuspid Repair?', JACC-CARDIOVASC INTE, vol. 10, no. 19, pp. 1982-1990. https://doi.org/10.1016/j.jcin.2017.08.011

APA

Taramasso, M., Hahn, R. T., Alessandrini, H., Latib, A., Attinger-Toller, A., Braun, D., Brochet, E., Connelly, K. A., Denti, P., Deuschl, F., Englmaier, A., Fam, N., Frerker, C., Hausleiter, J., Juliard, J-M., Kaple, R., Kreidel, F., Kuck, K. H., Kuwata, S., ... Leon, M. B. (2017). The International Multicenter TriValve Registry: Which Patients Are Undergoing Transcatheter Tricuspid Repair? JACC-CARDIOVASC INTE, 10(19), 1982-1990. https://doi.org/10.1016/j.jcin.2017.08.011

Vancouver

Taramasso M, Hahn RT, Alessandrini H, Latib A, Attinger-Toller A, Braun D et al. The International Multicenter TriValve Registry: Which Patients Are Undergoing Transcatheter Tricuspid Repair? JACC-CARDIOVASC INTE. 2017 Oct 9;10(19):1982-1990. https://doi.org/10.1016/j.jcin.2017.08.011

Bibtex

@article{2711b4bb03c04cdfabb72c5bf27520e7,
title = "The International Multicenter TriValve Registry: Which Patients Are Undergoing Transcatheter Tricuspid Repair?",
abstract = "OBJECTIVES: This study sought to develop a large, international registry to evaluate the diffusion of these approaches and investigate patient characteristics and initial clinical results.BACKGROUND: Several transcatheter tricuspid valve therapies are emerging as therapeutic options for patients with severe symptomatic tricuspid regurgitation (TR), generally a high-risk surgical population.METHODS: The TriValve (Transcatheter Tricuspid Valve Therapies) registry included 106 high-risk patients (76 ± 9 years of age; 60.4% women; European System for Cardiac Operative Risk Evaluation II 7.6 ± 5.7%) from 11 cardiac centers, with severe TR.RESULTS: A total of 35% of the patients had prior left heart valve intervention (surgical in 29 of 106 and transcatheter in 8 of 106 patients). Right ventricular (RV) dysfunction (tricuspid annular plane systolic excursion <17 mm) was present in 56.3% of the patients; 95% of the patients were in New York Heart Association functional class III to IV. The etiology of TR was functional in 95.2%, and the mean tricuspid annulus was 45.4 ± 11 mm. In 76.9% of the patients, the main location of the regurgitant jet was central; pre-procedural systolic pulmonary artery pressure was 39.7 ± 13.8 mm Hg; and the inferior vena cava was severely dilated in most of the patients (27.4 ± 6.8 mm). Implanted devices included MitraClip (n = 58), Trialign (n = 17), TriCinch (n = 15), FORMA (n = 7), Cardioband (n = 5), and caval valve implantation (n = 3). One case had combined Trialign + MitraClip. Patients treated with the different techniques were similar in terms of European System for Cardiac Operative Risk Evaluation II and degree of RV dysfunction. In 68% of the cases the tricuspid intervention was performed as an isolated procedure. Procedural success was achieved in 62% of cases. At 30-day follow-up, all-cause mortality was 3.7%, with an overall incidence of major adverse cardiac and cerebrovascular events of 26%; 58% of the patients were New York Heart Association functional class I or II at 30 days.CONCLUSIONS: Patients currently undergoing transcatheter tricuspid valve therapy are mostly high risk, with a functional etiology and very severe central regurgitation, and do not have severely impaired RV function. Initial results suggest that transcatheter tricuspid valve therapy is feasible with different techniques, but clinical efficacy requires further investigation.",
keywords = "Aged, Aged, 80 and over, Cardiac Catheterization/adverse effects, Clinical Decision-Making, Female, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation/adverse effects, Hemodynamics, Humans, Male, Patient Selection, Postoperative Complications/etiology, Prospective Studies, Prosthesis Design, Registries, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, Tricuspid Valve/diagnostic imaging, Tricuspid Valve Insufficiency/diagnostic imaging, Ventricular Function, Right",
author = "Maurizio Taramasso and Hahn, {Rebecca T} and Hannes Alessandrini and Azeem Latib and Adrian Attinger-Toller and Daniel Braun and Eric Brochet and Connelly, {Kim A} and Paolo Denti and Florian Deuschl and Andrea Englmaier and Neil Fam and Christian Frerker and Joerg Hausleiter and Jean-Michel Juliard and Ryan Kaple and Felix Kreidel and Kuck, {Karl Heinz} and Shingo Kuwata and Marco Ancona and Margarita Malasa and Tamim Nazif and Georg Nickenig and Fabian Nietlispach and Alberto Pozzoli and Ulrich Sch{\"a}fer and Joachim Schofer and Robert Schueler and Gilbert Tang and Alec Vahanian and Webb, {John G} and Ermela Yzeiraj and Francesco Maisano and Leon, {Martin B}",
note = "Copyright {\textcopyright} 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.",
year = "2017",
month = oct,
day = "9",
doi = "10.1016/j.jcin.2017.08.011",
language = "English",
volume = "10",
pages = "1982--1990",
journal = "JACC-CARDIOVASC INTE",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "19",

}

RIS

TY - JOUR

T1 - The International Multicenter TriValve Registry: Which Patients Are Undergoing Transcatheter Tricuspid Repair?

AU - Taramasso, Maurizio

AU - Hahn, Rebecca T

AU - Alessandrini, Hannes

AU - Latib, Azeem

AU - Attinger-Toller, Adrian

AU - Braun, Daniel

AU - Brochet, Eric

AU - Connelly, Kim A

AU - Denti, Paolo

AU - Deuschl, Florian

AU - Englmaier, Andrea

AU - Fam, Neil

AU - Frerker, Christian

AU - Hausleiter, Joerg

AU - Juliard, Jean-Michel

AU - Kaple, Ryan

AU - Kreidel, Felix

AU - Kuck, Karl Heinz

AU - Kuwata, Shingo

AU - Ancona, Marco

AU - Malasa, Margarita

AU - Nazif, Tamim

AU - Nickenig, Georg

AU - Nietlispach, Fabian

AU - Pozzoli, Alberto

AU - Schäfer, Ulrich

AU - Schofer, Joachim

AU - Schueler, Robert

AU - Tang, Gilbert

AU - Vahanian, Alec

AU - Webb, John G

AU - Yzeiraj, Ermela

AU - Maisano, Francesco

AU - Leon, Martin B

N1 - Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

PY - 2017/10/9

Y1 - 2017/10/9

N2 - OBJECTIVES: This study sought to develop a large, international registry to evaluate the diffusion of these approaches and investigate patient characteristics and initial clinical results.BACKGROUND: Several transcatheter tricuspid valve therapies are emerging as therapeutic options for patients with severe symptomatic tricuspid regurgitation (TR), generally a high-risk surgical population.METHODS: The TriValve (Transcatheter Tricuspid Valve Therapies) registry included 106 high-risk patients (76 ± 9 years of age; 60.4% women; European System for Cardiac Operative Risk Evaluation II 7.6 ± 5.7%) from 11 cardiac centers, with severe TR.RESULTS: A total of 35% of the patients had prior left heart valve intervention (surgical in 29 of 106 and transcatheter in 8 of 106 patients). Right ventricular (RV) dysfunction (tricuspid annular plane systolic excursion <17 mm) was present in 56.3% of the patients; 95% of the patients were in New York Heart Association functional class III to IV. The etiology of TR was functional in 95.2%, and the mean tricuspid annulus was 45.4 ± 11 mm. In 76.9% of the patients, the main location of the regurgitant jet was central; pre-procedural systolic pulmonary artery pressure was 39.7 ± 13.8 mm Hg; and the inferior vena cava was severely dilated in most of the patients (27.4 ± 6.8 mm). Implanted devices included MitraClip (n = 58), Trialign (n = 17), TriCinch (n = 15), FORMA (n = 7), Cardioband (n = 5), and caval valve implantation (n = 3). One case had combined Trialign + MitraClip. Patients treated with the different techniques were similar in terms of European System for Cardiac Operative Risk Evaluation II and degree of RV dysfunction. In 68% of the cases the tricuspid intervention was performed as an isolated procedure. Procedural success was achieved in 62% of cases. At 30-day follow-up, all-cause mortality was 3.7%, with an overall incidence of major adverse cardiac and cerebrovascular events of 26%; 58% of the patients were New York Heart Association functional class I or II at 30 days.CONCLUSIONS: Patients currently undergoing transcatheter tricuspid valve therapy are mostly high risk, with a functional etiology and very severe central regurgitation, and do not have severely impaired RV function. Initial results suggest that transcatheter tricuspid valve therapy is feasible with different techniques, but clinical efficacy requires further investigation.

AB - OBJECTIVES: This study sought to develop a large, international registry to evaluate the diffusion of these approaches and investigate patient characteristics and initial clinical results.BACKGROUND: Several transcatheter tricuspid valve therapies are emerging as therapeutic options for patients with severe symptomatic tricuspid regurgitation (TR), generally a high-risk surgical population.METHODS: The TriValve (Transcatheter Tricuspid Valve Therapies) registry included 106 high-risk patients (76 ± 9 years of age; 60.4% women; European System for Cardiac Operative Risk Evaluation II 7.6 ± 5.7%) from 11 cardiac centers, with severe TR.RESULTS: A total of 35% of the patients had prior left heart valve intervention (surgical in 29 of 106 and transcatheter in 8 of 106 patients). Right ventricular (RV) dysfunction (tricuspid annular plane systolic excursion <17 mm) was present in 56.3% of the patients; 95% of the patients were in New York Heart Association functional class III to IV. The etiology of TR was functional in 95.2%, and the mean tricuspid annulus was 45.4 ± 11 mm. In 76.9% of the patients, the main location of the regurgitant jet was central; pre-procedural systolic pulmonary artery pressure was 39.7 ± 13.8 mm Hg; and the inferior vena cava was severely dilated in most of the patients (27.4 ± 6.8 mm). Implanted devices included MitraClip (n = 58), Trialign (n = 17), TriCinch (n = 15), FORMA (n = 7), Cardioband (n = 5), and caval valve implantation (n = 3). One case had combined Trialign + MitraClip. Patients treated with the different techniques were similar in terms of European System for Cardiac Operative Risk Evaluation II and degree of RV dysfunction. In 68% of the cases the tricuspid intervention was performed as an isolated procedure. Procedural success was achieved in 62% of cases. At 30-day follow-up, all-cause mortality was 3.7%, with an overall incidence of major adverse cardiac and cerebrovascular events of 26%; 58% of the patients were New York Heart Association functional class I or II at 30 days.CONCLUSIONS: Patients currently undergoing transcatheter tricuspid valve therapy are mostly high risk, with a functional etiology and very severe central regurgitation, and do not have severely impaired RV function. Initial results suggest that transcatheter tricuspid valve therapy is feasible with different techniques, but clinical efficacy requires further investigation.

KW - Aged

KW - Aged, 80 and over

KW - Cardiac Catheterization/adverse effects

KW - Clinical Decision-Making

KW - Female

KW - Heart Valve Prosthesis

KW - Heart Valve Prosthesis Implantation/adverse effects

KW - Hemodynamics

KW - Humans

KW - Male

KW - Patient Selection

KW - Postoperative Complications/etiology

KW - Prospective Studies

KW - Prosthesis Design

KW - Registries

KW - Risk Factors

KW - Severity of Illness Index

KW - Time Factors

KW - Treatment Outcome

KW - Tricuspid Valve/diagnostic imaging

KW - Tricuspid Valve Insufficiency/diagnostic imaging

KW - Ventricular Function, Right

U2 - 10.1016/j.jcin.2017.08.011

DO - 10.1016/j.jcin.2017.08.011

M3 - SCORING: Journal article

C2 - 28982563

VL - 10

SP - 1982

EP - 1990

JO - JACC-CARDIOVASC INTE

JF - JACC-CARDIOVASC INTE

SN - 1936-8798

IS - 19

ER -